EGFR and lung carcinoma: In a search for additional substrates and interacting proteins using a ProtoAarrayTM [44] that contained ∼5000 recombinant proteins on the protein chip (www.invitrogen.com/protoarray), we found that AURKA interacted with the EGFR-L861Q mutant, which comprises ∼5% of EGFR mutations in lung cancer patients [10], but not EGFR-WT (Figure 4A).